Schadendorf, D., Long, G. V., Stroiakovski, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion-Sileni, V., Schachter, J., Garbe, C., Dutriaux, C., Gogas, H., Mandalà, M., Haanen, J. B., Lebbé, C., Mackiewicz, A., Rutkowski, P., Grob, J., Nathan, P., Ribas, A., Davies, M. A., Zhang, Y., Kaper, M., Mookerjee, B., Legos, J. J., Flaherty, K. T., & Robert, C. (2017). three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European journal of cancer, 82, 45–55. http://access.bl.uk/ark:/81055/vdc_100047869267.0x00000f